Altre lingue Cybin Inc.

Azioni

CYBN

CA23256X1006

Mercato chiuso - Nyse Altri mercati azionari 22:00:00 05/12/2023			Variaz. 5gg	Var. 1 gen.
0,4345 ^USD	-2,86%		-14,47%	+46,25%

30/11	Transcript : Cybin Inc. - Special Call	CI
30/11	Cybin Inc. riporta i dati topline positivi dello studio di Fase 2 di CYB003 nel Disturbo Depressivo Maggiore, con il 79% dei pazienti in remissione dopo due dosi da 12 mg.	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results	05/12
Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses	30/11
Cybin Inc. Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses	30/11
Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City	20/11
Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host R&D Briefing on November 30, 2023	16/11
Cybin Announces Closing of Offering of Units Led by One of the Company s Largest Institutional Shareholders	15/11
Cybin Announces Poster Presentation at Neuroscience 2023 Annual Meeting	15/11
Cybin Reports Second Quarter Financial Results and Recent Business Highlights	15/11
Cybin Announces Closing of Offering of Units Led by One of the Company’s Largest Institutional Shareholders	14/11
Cybin Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	14/11
Cybin Announces up to US$64 Million Offering of Units	13/11
Cybin : UNDERWRITING AGREEMENT - Form 6-K	13/11
Canadian Investment Regulatory Organization Trade Resumption - CYBN	10/11
Canadian Investment Regulatory Organization Trading Halt - CYBN	10/11
Cybin Announces up to US$64 Million Offering of Units	10/11
Cybin to Participate at the 2023 Milken Institute Future of Health Summit	03/11
Breakthrough Results: Cybin's CYB003 Demonstrates Remarkable Interim Data in Treating Major Depressive Disorder, Achieving Primary Efficacy Milestone and Delivering Prompt Relief from Depression Symptoms with a Single Dose - Comprehensive Topline Data Anticipated by Q4 2023	01/11
Cybin Provides Corporate Update and Highlights Key Upcoming Milestones Across its Development Pipeline	01/11
Cybin Inc. Provides Update on its Clinical-Stage Programs and Key Upcoming Milestones Across its Development Pipeline	01/11
Cybin dévoile des résultats provisoires jamais vus pour la phase 2 de CYB003 dans le traitement du trouble dépressif majeur : le paramètre primaire d'efficacité est atteint et une amélioration significative et rapide des symptômes dépressifs est...	01/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Transcript Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Cybin Inc.

Azioni

CYBN

CA23256X1006

Altre lingue

Filtri